Futoshi Kuribayashi

Futoshi Kuribayashi

Auto-generated profile, based on publicly available information

Futoshi Kuribayashi

Department of Biochemistry, Kawasaki Medical School, Kurashiki, Japan

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1997 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
DKDongchon Kang
Dongchon Kang
KMKenichi Miyako
Kenichi Miyako
FKFutoshi Kuribayashi
Futoshi Kuribayashi
EHEiji Hasegawa
Eiji Hasegawa
AMAtsushi Mitsumoto
Atsushi Mitsumoto
KTKoichiro Takeshige
Koichiro Takeshige

1 March 2021 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
HKHidehiko Kikuchi
Hidehiko Kikuchi
KHKaori Harata
Kaori Harata
Harishkumar MadhyasthaHarishkumar Madhyastha
Harishkumar Madhyastha
FKFutoshi Kuribayashi
Futoshi Kuribayashi
Ellagitannins (esters composed of glucose and ellagic acid) are hydrolyzed to generate ellagic acid in gut followed by conversion of ellagic acid to urolithins such as urolithin A by intestinal bacteria. Since urolithins are absorbed by gut easier than ellagitannins and ellagic acid, and show various physiological activities (e.g. anti-cancer, anti-cardiovascular disease, anti-diabetes mellitus, anti-obesity and anti-Alzheimer disease activities), they are expected as excellent health-promoting phytochemicals. Here, using human monoblast U937 cells, we investigated the effect of ellagic acid and urolithin A on the superoxide anion (O2−)-generating system of phagocytes, which is consisted of five specific protein factors (membrane proteins: p22-phox and gp91-phox, cytosolic proteins: p40-phox, p47-phox and p67-phox). Twenty micromolar of urolithin A enhanced the all-trans retinoic acid (ATRA)-induced O2−-generating activity (to ~175%) while 20 μM ellagic acid inhibited the ATRA-induced O2−-generating activity (to ~70%). Semiquantitative RT-PCR showed that transcription level of gp91-phox was certainly decreased (to ~70%) in ATRA plus ellagic acid-treated cells, while that of gp91-phox was significantly increased (to ~160%) in ATRA plus urolithin A-treated cells. Chromatin immunoprecipitation assay suggested that urolithin A enhanced acetylations of Lys-9 residues of histone H3 within chromatin surrounding the promoter region of gp91-phox gene, but ellagic acid suppressed the acetylations. Immunoblotting also revealed that ATRA plus urolithin A-treatment up-regulated protein levels of p22-phox (to ~160%) and gp91-phox (to ~170%) although ATRA plus ellagic acid-treatment down-regulated protein levels of p22-phox (to ~70%) and gp91-phox (to ~60%). These results suggested that conversion of ellagic acid to urolithin A in gut may bring about reverse effects on the gp91-phox gene expression, resulting in opposite alterations in O2−-generating activity of intestinal macrophages.

26 March 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
TTTetta Takahashi
Tetta Takahashi
NTNahoko Tomonobu
Nahoko Tomonobu
RKRie Kinoshita
Rie Kinoshita
KYKen-Ichi Yamamoto
Ken-Ichi Yamamoto
HMHitoshi Murata
Hitoshi Murata
Masakiyo SakaguchiMasakiyo Sakaguchi
Masakiyo Sakaguchi
Background: Our earlier research revealed that the secreted lysyl oxidase-like 4 (LOXL4) that is highly elevated in triple-negative breast cancer (TNBC) acts as a catalyst to lock annexin A2 on the cell membrane surface, which accelerates invasive outgrowth of the cancer through the binding of integrin-β1 on the cell surface. However, whether this machinery is subject to the LOXL4-mediated intrusive regulation remains uncertain.Methods: Cell invasion was assessed using a transwell-based assay, protein–protein interactions by an immunoprecipitation–Western blotting technique and immunocytochemistry, and plasmin activity in the cell membrane by gelatin zymography.Results: We revealed that cell surface annexin A2 acts as a receptor of plasminogen via interaction with S100A10, a key cell surface annexin A2-binding factor, and S100A11. We found that the cell surface annexin A2/S100A11 complex leads to mature active plasmin from bound plasminogen, which actively stimulates gelatin digestion, followed by increased invasion.Conclusion: We have refined our understanding of the role of LOXL4 in TNBC cell invasion: namely, LOXL4 mediates the upregulation of annexin A2 at the cell surface, the upregulated annexin 2 binds S100A11 and S100A10, and the resulting annexin A2/S100A11 complex acts as a receptor of plasminogen, readily converting it into active-form plasmin and thereby enhancing invasion.

6 October 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
ARAcosta Gonzalez Herik Rodrigo
Acosta Gonzalez Herik Rodrigo
NTNahoko Tomonobu
Nahoko Tomonobu
HYHaruka Yoneda
Haruka Yoneda
RKRie Kinoshita
Rie Kinoshita
YMYosuke Mitsui
Yosuke Mitsui
Masakiyo SakaguchiMasakiyo Sakaguchi
Masakiyo Sakaguchi
Bladder cancer is an often widely disseminated and deadly cancer. To block the malignant outgrowth of bladder cancer, we must elucidate the molecular-level characteristics of not only bladder cancer cells but also their surrounding milieu. As part of this effort, we have long been studying extracellular S100A8/A9, which is elevated by the inflammation associated with certain cancers. Extracellularly enriched S100A8/ A9 can hasten a shift to metastatic transition in multiple types of cancer cells. Intriguingly, high-level S100A8/A9 has been detected in the urine of bladder-cancer patients, and the level increases with the stage of malignancy. Nonetheless, S100A8/A9 has been investigated mainly as a potential biomarker of bladder cancers, and there have been no investigations of its role in bladder-cancer growth and metastasis. We herein report that extracellular S100A8/A9 induces upregulation of growth, migration and invasion in bladder cancer cells through its binding with cell-surface Toll-like receptor 4 (TLR4). Our molecular analysis revealed the TLR4 downstream signal that accelerates such cancer cell events. Tumor progression locus 2 (TPL2) was a key factor facilitating the aggressiveness of cancer cells. Upon binding of S100A8/A9 with TLR4, TPL2 activation was enhanced by an action with a TLR4 adaptor molecule, TIR domain-containing adaptor protein (TIRAP), which in turn led to activation of the mitogen-activated protein kinase (MAPK) cascade of TPL2. Finally, we showed that sustained inhibition of TLR4 in cancer cells effectively dampened cancer survival in vivo. Collectively, our results indicate that the S100A8/A9-TLR4-TPL2 axis influences the growth, survival, and invasive motility of bladder cancer cells. (c) 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1 January 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SOShuichiro Okamoto
Shuichiro Okamoto
KMKei Miyano
Kei Miyano
KKKeisuke Kitakaze
Keisuke Kitakaze
HKHitomi Kato
Hitomi Kato
Akira YamauchiAkira Yamauchi
Akira Yamauchi
FKFutoshi Kuribayashi
Futoshi Kuribayashi

21 January 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
YGYuma Gohara
Yuma Gohara
RKRie Kinoshita
Rie Kinoshita
NTNahoko Tomonobu
Nahoko Tomonobu
FJFan Jiang
Fan Jiang
YMYukiko Matsunaga
Yukiko Matsunaga
Masakiyo SakaguchiMasakiyo Sakaguchi
Masakiyo Sakaguchi
Contact hypersensitivity and atopic dermatitis are pervasive inflammatory skin diseases with similar symptoms, and their global prevalence is steadily increasing. Many compounds and biotics have been developed to target molecules critical to the etiology or pathogenesis of contact hypersensitivity and atopic dermatitis. However, these molecules are sometimes ineffective or lose their potency during the therapeutic course. Therefore, innovative medicines are still needed for the treatment of intractable cases. We focused on S100A8/A9, a heterodimer complex of S100A8 and S100A9 that is abundant in the extracellular milieu of inflammatory skin lesions. Although S100A8/A9 is primarily recognized as a diagnostic marker protein, we have previously shown that it also plays a crucial role in contact hypersensitivity and atopic dermatitis progression. This insight inspired us to develop its inhibitory antibody, leading to the ground-breaking Ab45. In this study, we demonstrated that Ab45 effectively prevented disease symptoms in various models and that its disease-ameliorating activity likely involved the downregulation of several disease-relevant molecules, including Il-23a, Il-36g, S100a8, and S100a9. We also created a humanized version of Ab45, HuAb45, which exhibited similar effectiveness. These antibodies show great promise for the treatment of contact hypersensitivity and atopic dermatitis and possibly for other inflammatory skin diseases.